Emergent's Narcan Reset Faces First Test As Revenue Is Expected To Nearly Halve

Three months ago Emergent BioSolutions traded its turnaround story for a reckoning. A strong second quarter, with revenue above the top of guidance and adjusted EBITDA of $97 million, was overshadowed by a sharp cut to the full-year outlook as new naloxone competitors chipped away at Narcan. The third-quarter report, due after the close on November 2, is the first chance to see whether that reset was a one-time clearing of the decks or the start of a longer slide.

The Street is braced for a steep drop. Consensus calls for a loss of $0.45 per share on revenue of $123.3 million, compared with earnings of $1.06 and revenue of $231.1 million a year ago. That is a revenue decline of nearly 47%. Management set this bar itself, guiding third-quarter revenue to $110 million to $130 million, so analysts sit just above the midpoint rather than reaching for upside. A print inside that range should not shock anyone. The more useful signal is how the company frames the rest of the year.

Some simple math shows why. First-half revenue came to roughly $390 million, and full-year guidance now stands at $645 million to $675 million. Pair that with the third-quarter range and the implied fourth quarter lands somewhere around $125 million to $175 million, with about $150 million at the midpoints. Hitting that requires either a rebound in medical countermeasure deliveries or Narcan holding up better than feared. Because the weak third quarter partly reflects government orders pulled into the first half, management needs to show the countermeasures business is merely lumpy, not shrinking. Contract award updates, the timing of deliveries and continued strength in international sales, which recently made up about a third of countermeasure revenue, will be the evidence.

Narcan is the bigger swing factor. Last quarter the company dropped its earlier view that commercial sales would be flat to slightly up and said it now expects continued price erosion as two new rivals enter. The key questions are how quickly pricing is deteriorating, whether volumes are holding, and whether line extensions such as the carrying case and multi-pack formats are helping defend share. Adjusted gross margin guidance was already lowered to 42% to 44%, so any hint that margins are tracking toward the bottom of that range would suggest the Narcan damage is outpacing the plan. Progress on the new $40 million cost-savings program, which is not expected to reach full run-rate until 2027, could cushion adjusted EBITDA against the cut range of $130 million to $150 million.

The balance sheet is the steadier part of the story. Gross debt fell to $590 million, net leverage held at 1.9 times, and the April refinancing pushed maturities out to 2031. Cash slipped to $140 million, but management cited $145 million of receivables collected through July, so the quarter-end cash figure should show whether those collections arrived. Any use of the new $75 million authorization to buy back senior notes would signal confidence in liquidity.

Sentiment has soured somewhat, moving to 10.8% bearish from 4.3% before the last report, yet the stock has gained 4.7% since then while the S&P 500 slipped 1.3%. At $6.23, shares remain well below the 200-day moving average of $8.19 and far beneath last quarter's $7.05 to $9.66 range, after bouncing off a post-report low of $4.36. The market appears to have priced in a lot of bad news without yet trusting a recovery. Whether Emergent can hold its reduced guidance without a second cut will decide if the August reset marked the bottom of the Narcan problem or only its first chapter.

This earnings preview was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It was generated automatically, with the help of AI, from Earnings Whispers and company data, and checked by Earnings Whispers before publication.